All Updates

All Updates

icon
Filter
Funding
Allogene Therapeutics to raise USD 110 million in underwritten offering
Human Gene Editing
May 13, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Today
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Yesterday
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Yesterday
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Yesterday
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Yesterday
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Yesterday
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Yesterday
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Yesterday
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Yesterday
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Yesterday
Human Gene Editing

Human Gene Editing

May 13, 2024

Allogene Therapeutics to raise USD 110 million in underwritten offering

Funding

  • Allogeneic CAR T therapy developer Allogene Therapeutics has announced the price for an underwritten offering of 37.9 million common shares at a rate of USD 2.90 per share. Mutual funds, large institutional investors, healthcare specialists, and certain members of Allogene's board and executive management team will also participate in the offering.

  • The offering, which is expected to close on or about May 16, 2024, is expected to raise USD 110 million in overall gross proceeds. 

  • Allogene focuses on offering off-the-shelf CAR T therapies. It develops allogeneic chimeric antigen receptor T-cell (AlloCAR T) products to treat cancers and autoimmune diseases. The company leverages multiplex gene-engineering and gene-editing technologies to offer off-the-shelf T-cell therapies designed to be more scalable and cost-effective than autologous counterparts. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.